Hester Biosciences Limited Stock Price Today (NSE: HESTERBIO)
Fundamental Score
Hester Biosciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Hester Biosciences Limited share price today is ₹2207.70, up +1.65% on NSE/BSE as of 16 September 2026. Hester Biosciences Limited (HESTERBIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.88K (Cr). The 52-week high for HESTERBIO share price is ₹2683.60 and the 52-week low is ₹1239.30. At a P/E ratio of 13.72x, HESTERBIO is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 16.50% and a debt-to-equity ratio of 0.52.
Hester Biosciences Limited Share Price Chart — NSE/BSE Historical Performance
Hester Biosciences Limited share price chart: -6.87% return over the past month. 52-week high ₹2683.60, 52-week low ₹1239.30.
Hester Biosciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2147.00 | ₹2305.00 | ₹2130.00 | ₹2207.70 | 4.57K (Cr) | |
| ₹2271.00 | ₹2299.00 | ₹2151.50 | ₹2171.80 | 4.44K (Cr) | |
| ₹2275.00 | ₹2298.90 | ₹2238.30 | ₹2264.90 | 5.28K (Cr) | |
| ₹2323.00 | ₹2343.90 | ₹2267.50 | ₹2279.00 | 3.07K (Cr) | |
| ₹2316.90 | ₹2360.00 | ₹2257.40 | ₹2322.60 | 3.78K (Cr) | |
| ₹2354.70 | ₹2369.90 | ₹2290.00 | ₹2318.30 | 5.57K (Cr) | |
| ₹2405.40 | ₹2405.40 | ₹2330.10 | ₹2362.70 | 8.15K (Cr) | |
| ₹2199.90 | ₹2540.90 | ₹2170.00 | ₹2405.40 | 93.54K (Cr) | |
| ₹2176.50 | ₹2225.00 | ₹2176.50 | ₹2201.70 | 1.97K (Cr) | |
| ₹2189.50 | ₹2210.90 | ₹2146.00 | ₹2176.50 | 7.01K (Cr) |
Hester Biosciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2257.50 | ₹2540.90 | ₹2130.00 | ₹2207.70 | -2.21% | |
| ₹2477.00 | ₹2546.80 | ₹2255.50 | ₹2258.90 | -8.81% | |
| ₹2164.90 | ₹2683.60 | ₹2058.27 | ₹2477.70 | +14.45% | |
| ₹2030.00 | ₹2315.00 | ₹1910.20 | ₹2165.90 | +6.69% | |
| ₹1615.40 | ₹2238.70 | ₹1613.60 | ₹2009.20 | +24.38% | |
| ₹1275.00 | ₹1800.00 | ₹1275.00 | ₹1634.20 | +28.17% | |
| ₹1502.00 | ₹1560.00 | ₹1239.30 | ₹1259.10 | -16.17% | |
| ₹1530.00 | ₹1629.00 | ₹1476.70 | ₹1562.10 | +2.10% | |
| ₹1602.50 | ₹1644.00 | ₹1360.30 | ₹1483.80 | -7.41% | |
| ₹1657.30 | ₹1660.00 | ₹1552.70 | ₹1599.70 | -3.48% | |
| ₹1603.30 | ₹1780.00 | ₹1573.70 | ₹1653.90 | +3.16% | |
| ₹1919.70 | ₹1919.70 | ₹1581.10 | ₹1603.30 | -16.48% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Hester Biosciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Hester Biosciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HESTERBIO across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (16.50%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (15.26%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.11%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 13.72 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (489.84%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Interest Coverage (7.35x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.56)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (53.73%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
High Price-to-Book Ratio (5.98x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Revenue Contraction (-8.16%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-27.14 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.38%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Hester Biosciences Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Hester Biosciences Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Hester Biosciences LimitedHester Bioscien...Selected✓ HESTERBIO • 524669 | 50.9/100 | ₹2207.70₹2208 | ₹1878.09₹1878.09 | 13.72Average 13.7 Average | 16.50%Good 16.50% Good | 15.26%Good 15.26% Good | 0.52Good 0.5 Good | 10.08%Good 10.08% Good | 9.19%Good 9.19% Good | 0.46% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Hester Biosciences Limited PE Ratio History
Historical price-to-earnings ratio for HESTERBIO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹32.31 | ₹1599.70 | 49.5x |
| FY 2024 | ₹22.20 | ₹2399.40 | 108.1x |
| FY 2023 | ₹31.30 | ₹1457.90 | 46.6x |
| FY 2022 | ₹46.22 | ₹1791.65 | 38.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Hester Biosciences Limited Dividend History
Annual cash dividends paid by HESTERBIO — dividend yield 0.46%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹5.17 Cr |
| FY 2024 | ₹6.85 Cr |
| FY 2023 | ₹8.51 Cr |
| FY 2022 | ₹8.51 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Hester Biosciences Limited Quarterly Performance
Latest quarterly metrics for HESTERBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-8.16%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
489.84%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.19%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
10.08%
Compounded annual net profit growth over 5 years
Hester Biosciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for HESTERBIO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Hester Biosciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Hester Biosciences Limited (HESTERBIO) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Hester Biosciences Limited
About HESTERBIO (Hester Biosciences Limited)
Hester Biosciences Ltd is a dynamic pharmaceutical company dedicated to safeguarding animal health through innovative solutions. They specialize in the development, manufacturing, ...and distribution of a comprehensive range of veterinary vaccines and animal health products, catering to both domestic and international markets. With a commitment to preventing diseases and improving livestock productivity, Hester Biosciences operates through dedicated divisions focused on Poultry Healthcare and Animal Healthcare. These divisions work synergistically to deliver tailored solutions addressing the unique needs of different animal species and farming practices. The company's dedication to research and development drives the creation of cutting-edge vaccines, ensuring effective protection against prevalent and emerging animal diseases. Hester Biosciences' Poultry Healthcare segment provides a wide array of vaccines, specifically formulated to protect poultry flocks from debilitating diseases. The company offers vaccines against Newcastle disease, a highly contagious viral infection, as well as Infectious Bronchitis, a respiratory illness affecting poultry. Their product portfolio also includes vaccines for Infectious Bursal disease, Fowl Pox, Marek's disease, Infectious Coryza, Fowl Cholera, Inclusion Body Hepatitis, Fowl Typhoid, and Avian Encephalomyelitis. These vaccines are designed to stimulate the immune system of poultry, providing robust protection against these common diseases and improving overall flock health and productivity. Hester Biosciences is deeply invested in the poultry industry's success and actively supports farmers in maintaining healthy and profitable operations. Beyond poultry, Hester Biosciences' Animal Healthcare segment is dedicated to developing and distributing vaccines for livestock. These vaccines are designed to protect animals from Peste des Petits Ruminants (PPR), a devastating disease affecting small ruminants. In addition to vaccines, the company also offers animal health products, providing holistic solutions for animal welfare. Hester Biosciences focuses on building strong relationships with veterinarians and farmers, delivering specialized support and assistance to enhance animal health outcomes. By providing quality vaccines and animal health products, Hester Biosciences contributes to improved animal health and sustainable livestock production, ultimately benefiting farmers and consumers alike.
Company Details
Key Leadership
HESTERBIO Share Price: Frequently Asked Questions
What is the current share price of Hester Biosciences Limited?
Hester Biosciences Limited (HESTERBIO) trades at ₹2207.70 on NSE and BSE. Market cap ₹1.88K (Cr). Educational data only.
What is the P/E ratio of Hester Biosciences Limited?
Hester Biosciences Limited has a P/E of 13.72x vs industry average 34.89x.
What is the Bull Run score for Hester Biosciences Limited?
Hester Biosciences Limited has a Bull Run score of 50.9/100 based on 25+ financial parameters.
Does Hester Biosciences Limited pay dividends?
Hester Biosciences Limited has a dividend yield of 0.46%. Past dividends don't guarantee future payments.
What is the ROE of Hester Biosciences Limited?
Hester Biosciences Limited has ROE of 16.50%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Hester Biosciences Limited?
Hester Biosciences Limited has debt-to-equity of 0.52.
Is Hester Biosciences Limited a good investment?
Bull Run gives Hester Biosciences Limited a score of 50.9/100. This is not investment advice — consult a SEBI-registered advisor.